Last reviewed 2026-05-27 · How we verify

Moxonidine Pill

Vanderbilt University Medical Center · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Moxonidine Pill is a Small molecule drug developed by Vanderbilt University Medical Center. It is currently in Phase 1 development. Also known as: Physiotens.

Moxonidine is a small molecule that acts as an agonist to the molecular target Nischarin. It has been studied as a potential treatment for conditions such as Postural Tachycardia Syndrome and Diabetic Nephropathies.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Moxonidine Pill
Also known as	Physiotens
Sponsor	Vanderbilt University Medical Center
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Autonomic Determinants of POTS - Pilot1 (EARLY_PHASE1)
Autonomic Determinants of POTS - Pilot 2 (EARLY_PHASE1)
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Moxonidine Pill CI brief — competitive landscape report
Moxonidine Pill updates RSS · CI watch RSS
Vanderbilt University Medical Center portfolio CI

Frequently asked questions about Moxonidine Pill

What is Moxonidine Pill?

Moxonidine Pill is a Small molecule drug developed by Vanderbilt University Medical Center.

Who makes Moxonidine Pill?

Moxonidine Pill is developed by Vanderbilt University Medical Center (see full Vanderbilt University Medical Center pipeline at /company/vanderbilt-university-medical-center).

Is Moxonidine Pill also known as anything else?

Moxonidine Pill is also known as Physiotens.

What development phase is Moxonidine Pill in?

Moxonidine Pill is in Phase 1.

Manufacturer: Vanderbilt University Medical Center — full pipeline
Also known as: Physiotens

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing